A comprehensive, quantitative understanding of patient progression through all stages of disease management and treatment is critical in both assessing a market opportunity within a therapeutic area and developing a product positioning strategy. DRG’s Patient Journey: EHR and Claims Data Analysis combines analytics with therapy expert insights to illuminate the patients’ path from disease presentation through diagnosis and treatment, highlighting their demographic and clinical features and intersections with key healthcare stakeholders. The patient journey analysis provides a granular roadmap for developers, quantifying key patient segments and identifying intervention points along the disease management continuum to support business decisions spanning opportunity assessment and all drug development stages.

Table of contents

  • Detailed, Expanded Analysis: Patient Journey: EHR and Claims Data Analysis (US)
    • Patient Journey - Chronic Heart Failure - 2019 - US

Author(s): Melissa Curran; Conor Walsh; Graeme Green, PhD, MSc

Melissa Curran is a Principal Analyst in the Solution Development group at Decision Resources Group. She has experience conducting opportunity assessments, competitive intelligence, forecasting and primary market research with physicians and payers across a diverse range of therapeutic areas from her previous tenure in both the Consulting and Immune and Inflammatory groups at DRG. Melissa received her BA in biology and minor in business from Providence College.

Conor Walsh, , is a Senior Director on the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources. Prior to joining Decision Resources, he worked at Medical Marketing Research International. Dr. Walsh holds an in bioinformatics and a in cardiac structural biology, both from the University of Manchester. For his doctoral work, he studied the molecular mechanisms underlying heart failure. Dr. Walsh earned his in biotechnology with first class honors from the National University of Ireland in Galway.

Graeme Green, , is a director of Decision Resources Group's Cardiovascular, Metabolic and Renal team, where he is focused on the group’s hematology and cardiovascular coverage. He also leads the team’s commercial and therapeutic landscape ; Dr. Green joined DRG in 2007 as a cardiovascular analyst and has authored insight reports covering market dynamics and drug development. Dr. Green holds a in molecular medical microbiology from King’s College London, he also holds an in forensic science and a in biomedical sciences, both also from King’s College. Prior to joining DRG Dr. Green worked for a financial management consultancy.


Related Reports

Heart Failure | Current Treatment | Detailed, Expanded Analysis - Chronic Heart Failure - Preserved Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s pathoph...

View Details

Heart Failure | Current Treatment | Detailed, Expanded Analysis - Chronic Heart Failure - Reduced Ejection Fraction - Treatment Algorithms - Claims Data Analysis - US

Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF...

View Details

Heart Failure | Current Treatment | Detailed, Expanded Analysis: Chronic Heart Failure - Treatment Algorithms: Claims Data Analysis (US)

First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or thi...

View Details

Heart Failure | Landscape & Forecast | Disease Landscape & Forecast

Heart failure (HF) is categorized into acute or chronic, and both settings are the focus of this report. While much progress has been made in the pharmacological management of HF, it mainly...

View Details